A Novo Nordisk executive outlined the scientific rationale behind testing Semaglutide in Alzheimer’s disease at a meeting on Tuesday.
Novo Nordisk (NVO) reportedly defended its decision to test Semaglutide, its GLP-1 therapy, in Alzheimer’s disease on Tuesday, saying it launched pivotal trials in 2020 based on evidence from human studies, animal research and real-world findings.
Speaking at the Clinical Trials in Alzheimer’s Disease meeting in San Diego, Peter Johannsen, Novo’s international medical vice president, acknowledged criticism that the studies had design flaws, according to a Reuters report.
He supposedly said the lack of statistically significant slowing of cognitive decline did not change the rationale for conducting them, calling it “a scientific question that needed an answer.”
Get updates to this developing story directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
-
Moin Khan refutes death rumours, confirms he Is healthy
-
Woman Claims Her Landlord Is Trying To Charge Her More Rent For Her Newborn
-
One-Card Tarot Horoscopes For Each Zodiac Sign On December 3, 2025
-
Tech YouTuber Marques Brownlee to shut down wallpapers app
-
Bending Spoons agrees to buy Eventbrite for $500M to revive stalled brand
